Julian Downward

Associate Research Director

The Francis Crick Institute
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (60)

Year:

2026

Year:

2026

Genetic disruption of the RAS binding domain (RBD) of phosphoinositide 3-kinase alpha (PI3Kα) impairs the growth of tumors driven by the small guanosine triphosphatase RAS in mice and does not affect PI3Kα’s role in insulin-mediated control of glucose homeostasis. Selectively blocking the RAS-PI3Kα interaction may represent a strategy for treating RAS-dependent cancers as it avoids the toxicity associated with inhibitors of PI3Kα lipid kinase activity. We developed compounds that bind covalently to cysteine 242 in the RBD of PI3K p110α and block RAS activation of PI3Kα activity. In mice, inhibitors slow the growth of RAS mutant tumors and human epidermal growth factor receptor 2–overexpressing tumors, particularly when combined with other inhibitors of the RAS/mitogen-activated protein kinase pathway, without causing hyperglycemia.

Year:

2025

Year:

2025

Lung adenocarcinoma (LUAD) is a leading cause of cancer death worldwide, with RAS signalling as a key oncogenic driver. Although KRAS mutations have been linked to immune evasion in preclinical models, the relationship between RAS activity and tumour immunity or response to immunotherapy in patients remains unclear. Here, we applied our previously validated RAS84 transcriptional signature to stratify LUAD patient cohorts and dissect the immune landscape associated with RAS signalling. We report that tumours with elevated RAS activity exhibited features of immune priming, including increased immune infiltration, interferon response, and immune checkpoint gene expression, and showed improved progression-free survival in an independent cohort of patients treated with anti-PD-1. Yet, in both LUAD tumours and cell lines, RAS activity also correlated with elevated immunosuppressive interstitial adenosine mediated by transcriptional regulation of several components of the adenosinergic pathway. In orthotopic pre-clinical models of high-RAS activity lung tumours, blocking adenosine signalling delayed tumour growth and improved response to anti-PD-1 and KRAS inhibition, with a significant effect on innate immunity. This study reveals a dual role for RAS signalling in tumour progression, fostering a pro-immunogenic environment whilst simultaneously dampening anti-tumoural immunity via mechanisms including extracellular adenosine accumulation. Stratifying patients based on RAS transcriptional activity, rather than genetic alterations alone, could inform immunotherapy strategies and improve clinical outcomes.

Year:

2025

The response of lung cancer patients to drugs targeting the G12C mutant form of KRAS is limited by the development of resistance through multiple mechanisms. In order to achieve lasting benefit with these therapies, effective strategies for tackling the evolution of drug resistance are required. We have developed a preclinical model system to mimic the development of resistance to KRAS G12Ci inhibitors (G12Ci) such as adagrasib and RMC-4998. Treatment of tumours containing a minor subpopulation of resistant cancer cells with G12Ci leads to their rapid outgrowth to replace the drug-sensitive cells within a few weeks. However, when combined with therapies that, at least in part, target the immune response, such as SHP2 inhibitors or PD-1 blockade, drug-resistant cells can be eliminated, even by drug combinations that do not impact their growth in the absence of drug-sensitive cells. This bystander killing of drug-resistant cells when drug-sensitive cells are targeted is dependent on an intact adaptive immune system. Mechanistically, these combination therapies lead to profound remodelling of the tumour immune microenvironment, with influx of T cells recognising a tumour associated antigen shared between drug-resistant and drug-sensitive cancer cells. Promotion of immune-mediated bystander killing of drug-resistant cells may provide a paradigm for tackling the problem of drug resistance in cancer more broadly.

Year:

2025

High-grade serous ovarian cancer demonstrates limited responsiveness to immune checkpoint inhibitors, owing in part to immunosuppressive environments shaped by nearly universal p53 aberrations. Utilizing an immunocompetent mouse model and individual p53 mutations, we identified a dependence of the p53-R270H mutation (equivalent of human R273H) on regulatory T cells (Tregs) and the PD-1/PD-L1 axis. Analysis of patient datasets associated R273H with elevated levels of two p53 targets, PD-L1 and amphiregulin (AREG), a Tregs growth factor. In contrast to p53-R172H tumors, where there was limited activity, dual antibody therapy targeting AREG and PD-L1 selectively and effectively inhibited R270H tumors. This involved polarization toward M1 macrophages, infiltration of CD8+ T cells, diminished Ly6G+ neutrophils and downregulation of interleukin-4. In patient-derived R273C organoids, the combination treatment reduced the CD4/CD8 ratio. This study is the first to establish a mutation-tailored therapeutic approach that leverages the capacity of p53 to modulate immunosuppressive mechanisms.

Year:

2025

Cotargeting of MEK1/2 and the RAC1 effector p110β suppresses growth of melanoma lines in vitro . A, Left, relative confluence of WM266.4 cells treated with indicated treatments over time. Representative of a minimum of five independent experiments and three technical replicates. Data, mean ± SEM (confluence relative to starting point). Right, relative change in confluence of WM266.4 cells over indicated 72-hour treatment. Center line, mean. P values calculated by one-way ANOVA corrected for multiple comparisons (Tukey). B, Left, relative confluence of A375 cells treated with indicated treatments over time. Representative of three independent experiments with a minimum of three technical replicates. Data, mean ± SEM (confluence relative to starting point). Right, relative change in confluence of A375 cells over indicated 72-hour treatment. Center line, mean. P values calculated by one-way ANOVA corrected for multiple comparisons (Tukey). C, Fluorescence labeled (LI-COR) immunoblotting for indicated activated components of the MAPK–PI3K–mTOR pathway in the indicated human melanoma cells treated with vehicle or the indicated targeted therapeutics. Co-labeled total protein detection for each phosphoprotein serves as a sample integrity control. The blots are representative of three repeated experiments. D, RPPA dataset comparing PTEN-deficient and PTEN-proficient melanoma cell lines treated with indicated treatments for 24 hours. Cell line names and treatments are indicated below the heatmap. Antigens, detected by RPPA antibodies, are listed vertically according to biological process/signaling pathway. Color intensity scale indicates high (red) and low (blue) log 2 FC of RPPA intensity values relative to the relevant DMSO control. Results are representative of two technical and five biological replicates per condition.

Year:

2025

Genetic targeting of p110β and its interaction with RAC1 sensitizes to MEK1/2 inhibition in vitro and in vivo. A, Left, flow cytometry–based cell-cycle profiling of WM266.4 cells following indicated 24-hour treatment. Right, proportion of WM266.4 cells in G 1 /S at 24 hours. n = 3 independent experiments. P values calculated by one-way ANOVA corrected for multiple comparisons (Tukey). B, Left, flow cytometry–based cell-cycle profiling of A375 cells following indicated 24 hours treatment. Middle, proportion of A375 cells in G 1 /S at 24 hours. Right, proportion of subdiploid A375 cells at 24 hours. n = 4 independent experiments. P values calculated by one-way ANOVA corrected for multiple comparisons (Tukey). C, Left, Kaplan–Meier overall survival of BRAF PTEN mice treated with vehicle or AZD6244. BRAF PTEN + vehicle ( n = 8; median survival, 12.5 days) vs. BRAF PTEN + AZD6244 ( n = 8; median survival, 74.5 days), P = 0.0096; BRAF PTEN PIK3CB-mut + vehicle ( n = 4; median survival, 11.5 days) vs. BRAF PTEN PIK3CB-mut + AZD6244 ( n = 7; median survival, 83 days), P = 0.0082; BRAF PTEN + AZD6244 ( n = 8; median survival, 74.5 days) vs. BRAF PTEN PIK3CB-mut + AZD6244 ( n = 7; median survival, 83 days), P = 0.1643. P values calculated using the log-rank (Mantel–Cox) test. Middle, longitudinal growth of individual tumors from vehicle-treated ( n = 8) vs. AZD6244-treated ( n = 7) BRAF PTEN cohorts and vehicle-treated ( n = 5) vs. AZD6244-treated ( n = 7) BRAF PTEN PIK3CB-mut cohorts. Right, relative change in tumor volume over the first 7 days of indicated treatment. BRAF PTEN + vehicle ( n = 8), BRAF PTEN + AZD6244 ( n = 7), BRAF PTEN PIK3CB-mut + vehicle ( n = 5), BRAF PTEN PIK3CB-mut + AZD6244 ( n = 6); P values calculated by one-way ANOVA corrected for multiple comparisons (Tukey). Center line, mean. Note that the BRAF PTEN treatment datasets are reproduced from Fig. 2A and C . D, Left, relative confluence of WM266.4 PIK3CB KO cells treated with indicated treatments over the 96-hour period. Representative of a minimum of three independent experiments and three technical replicates. Data, mean ± SEM (confluence relative to starting point). Right, relative change in confluence of WM266.4 PIK3CB KO cells over the indicated 96-hour period. Center line, mean. P values calculated by one-way ANOVA corrected for multiple comparisons (Tukey).

Year:

2025

Functional loss of PREX2 function sensitizes to MAPK inhibition in vitro and in vivo . A, Left, Kaplan–Meier overall survival of mice with the indicated genotypes and treatments. BRAF PTEN + vehicle ( n = 8; median survival, 12.5 days) vs. BRAF PTEN + AZD6244 ( n = 8; median survival, 74.5 days), P = 0.0096; BRAF PTEN PREX2 + vehicle, ( n = 7; median survival, 13 days) vs. BRAF PTEN PREX2 + AZD6244 ( n = 8; median survival, 108.5 days), P = 0.00005; BRAF PTEN + AZD6244 ( n = 8; median survival, 74.5 days) vs. BRAF PTEN PREX2 + AZD6244 ( n = 8; median survival, 108.5 days), P = 0.0021 log-rank (Mantel–Cox) test. Middle, longitudinal growth of individual tumors from vehicle-treated ( n = 8) vs. AZD6244-treated ( n = 7) BRAF PTEN cohorts and vehicle-treated ( n = 7) vs. AZD6244-treated ( n = 8) BRAF PTEN PREX2 cohorts. Right, relative change in tumor volume in mice with the indicated genotypes over the first 7 days of indicated treatment. BRAF PTEN + vehicle ( n = 8), BRAF PTEN + AZD6244 ( n = 7), BRAF PTEN PREX2 + vehicle ( n = 7), BRAF PTEN PREX2 + AZD6244 ( n = 8). P values were calculated by one-way ANOVA corrected for multiple comparisons (Tukey). B, Left, Kaplan–Meier overall survival of mice with the indicated genotypes and treatments. BRAF P53 + vehicle ( n = 7; median survival, 14 days) vs. BRAF P53 + AZD6244 ( n = 9; median survival, 26 days), P = 0.0204; BRAF P53 PREX2 + vehicle ( n = 5; median survival, 14 days) vs. BRAF P53 PREX2 + AZD6244 ( n = 8; median survival, 39 days), P = 0.0010; BRAF P53 + AZD6244 ( n = 8; median survival, 14.5 days) vs. BRAF P53 PREX2 + AZD6244 ( n = 10; median survival, 35 days), P = 0.0034. P values calculated using the log-rank (Mantel–Cox) test. Middle, longitudinal growth of individual tumors from vehicle-treated ( n = 5) vs. AZD6244-treated ( n = 4) BRAF P53 cohorts and vehicle-treated ( n = 7) vs. AZD6244-treated ( n = 6) BRAF P53 PREX2 cohorts. Right, relative change in tumor volume over the first 7 days of indicated treatment. BRAF P53 + vehicle ( n = 5), BRAF P53 + AZD6244 ( n = 4), BRAF P53 PREX2 + vehicle ( n = 5), BRAF P53 PREX2 + AZD6244 ( n = 6); P values, one-way ANOVA corrected for multiple comparisons (Tukey). C, Left, Kaplan–Meier overall survival of BRAF PTEN and BRAF PTEN PREX2-GD cohorts treated with vehicle or AZD6244. BRAF PTEN + vehicle ( n = 8; median survival, 12.5 days) vs. BRAF PTEN + AZD6244 ( n = 8; median survival, 74.5 days), P = 0.0096; BRAF PTEN PREX2-GD + vehicle ( n = 6; median survival, 11 days) vs. BRAF PTEN PREX2-GD + AZD6244 ( n = 8; median survival, 100.5 days), P = 0.0002; BRAF PTEN + AZD6244 ( n = 8; median survival, 74.5 days) vs. BRAF PTEN PREX2-GD + AZD6244 ( n = 8; median survival, 100.5 days), P = 0.0414. P values calculated using the log-rank (Mantel–Cox) test. Middle, longitudinal growth of individual tumors from vehicle-treated ( n = 8) vs. AZD6244-treated ( n = 7) BRAF PTEN cohorts and vehicle-treated ( n = 6) vs. AZD6244-treated ( n = 8) BRAF PTEN PREX2-GD cohorts. Right, relative change in tumor volume over the first 7 days of indicated treatment. BRAF PTEN + vehicle ( n = 8), BRAF PTEN + AZD6244 ( n = 7), BRAF PTEN PREX2-GD + vehicle ( n = 5), BRAF PTEN PREX2-GD + AZD6244 ( n = 6). P values calculated by one-way ANOVA corrected for multiple comparisons (Tukey). Note that the same BRAF PTEN treatment datasets are represented in A and C . D, Top left, relative confluence of parental WM266.4 cells treated with indicated treatments over the 96-hour period. Representative of a minimum of three independent experiments and three techni

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (35)

Philip Hobson

Deputy Head of Flow Cytometry

The Francis Crick Institute

UNITED KINGDOM
View details

Mihaela Angelova

The Francis Crick Institute

UNITED KINGDOM
View details

Miriam Molina Arcas

The Francis Crick Institute

UNITED KINGDOM
View details

Charles Swanton

Chief Clinician

-

UNITED KINGDOM
View details

Philip East

Deputy Head

Institut Gustave Roussy

FRANCE
View details

DANA KOLUDROVIC

Cancer Research UK Beatson Institute

UNITED KINGDOM
View details

Se‐Hoon Lee

-

SOUTH KOREA
View details

Mariam Jamal-Hanjani

Group Leader and Thoracic Oncologist

University College London

UNITED KINGDOM
View details

Fiona Blackhall

The University of Manchester

UNITED KINGDOM
View details

Clare Puttick

The Francis Crick Institute

UNITED KINGDOM
View details

James D Brenton

University of Cambridge

UNITED KINGDOM
View details

Kevin Litchfield

University College London

UNITED KINGDOM
View details

Philip Dunne

Group Leader

Cancer Research UK Beatson Institute

UNITED KINGDOM
View details

Timothy Wallis

Honorary Senior Clinical Lecturer

University of Southampton

UNITED KINGDOM
View details

Selvaraju Veeriah

University College London

UNITED KINGDOM
View details

Krijn Dijkstra

The Netherlands Cancer Institute

NETHERLANDS
View details

Christopher Moore

senior research scientist

The Francis Crick Institute

UNITED KINGDOM
View details

JAMES READING

University College London

UNITED KINGDOM
View details

Katey Enfield

Assistant Professor

The University of British Columbia

CANADA
View details

Allan Hackshaw

University College London

UNITED KINGDOM
View details

Pedro Rodriguez Cutillas

Profresor de Investigación

Instituto de Parasitología y Biomedicina López-Neyra

SPAIN
View details

James MacRae

Head of metabolomics

The Francis Crick Institute

UNITED KINGDOM
View details

James Black

University College London

UNITED KINGDOM
View details

Mark Jones

Professor of Respiratory Medicine

University of Southampton

UNITED KINGDOM
View details

Marie Pariollaud

Vivatides Therapeutics Inc.

UNITED STATES
View details

Owen J. Sansom

Director

Cancer Research UK Beatson Institute

UNITED KINGDOM
View details

Nathan Goehring

Associate Professor

University of Oxford

UNITED KINGDOM
View details

Andrew D Campbell

Research Team Leader

Cancer Research UK Beatson Institute

UNITED KINGDOM
View details

Sophie de Carne

Junior Group Leader

Institut Gustave Roussy

FRANCE
View details

Sergio Quezada

University College London

UNITED KINGDOM
View details

Neil Carragher

Professor

University of Edinburgh

UNITED KINGDOM
View details

Santiago Zelenay

Group Leader

Cancer Research UK Manchester Institute

UNITED KINGDOM
View details

Erik Sahai

The Francis Crick Institute

UNITED KINGDOM
View details

Mary Green

Deputy Head of Experimental Histopathology

The Francis Crick Institute

UNITED KINGDOM
View details

BEN MARSHALL

Consultant in respiratory medicine and Honorary Associate Professor

University Hospital Southampton NHS Foundation Trust

UNITED KINGDOM
View details